We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current CLVLY market cap is 383.47M. The company's latest EPS is AUD 0.7109 and P/E is 16.98.
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 32.69M | 48.11M | 65.94M | 78.34M | 88.74M |
| Operating Income | 10.33M | 26.83M | 33.27M | 40.94M | 44.12M |
| Net Income | 15.05M | 24.73M | 20.88M | 30.61M | 35.64M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 81.54M | 108.57M | 143.95M | 193.71M | 231.12M |
| Total Liabilities | 9.48M | 9.83M | 18.39M | 29.08M | 28.11M |
| Total Equity | 72.07M | 98.74M | 125.56M | 164.63M | 203.01M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | 14.19M | 19.26M | 39.87M | 36.91M | 37.05M |
| Investing | -888k | -854k | -434k | -31.85M | -29.03M |
| Financing | -1.49M | -1.48M | -1.5M | -2.24M | -3.57M |
| Market Cap | 383.47M |
| Price to Earnings Ratio | 16.98 |
| Price to Sales Ratio | 6.82 |
| Price to Cash Ratio | 3.29 |
| Price to Book Ratio | 2.98 |
| Dividend Yield | 0.39% |
| Shares Outstanding | 50.13M |
| Average Volume (1 week) | 1.82k |
| Average Volume (1 Month) | 3.41k |
| 52 Week Change | -23.50% |
| 52 Week High | 11.40 |
| 52 Week Low | 6.80 |
| Spread (Intraday) | 0.68 (8.53%) |
| Company Name | Clinuvel Pharmaceuticals Ltd (PK) |
| Address |
level 11 melbourne, victoria 3000 |
| Website | https://www.clinuvel.com |
| Industry | drugs-health r&d/testing labs (H8) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
